Takeda Signs Option to Market Ascentage’s Blood-Cancer Drug

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Takeda Pharmaceutical Co. signed an option agreement with Chinese drug developer Ascentage Pharma Group International for the development of a blood-cancer drug, as the Japanese drug maker attempts to revive its drug pipeline and boost growth.

Meloni Uses the G-7 to Put Focus on the Global South — And HerselfJunk Bonds From Asia Beat Most Everything Else: Credit WeeklyFrance Prepares for Far-Right Protests as Le Pen Leads the PollsThe Market Is Blowing Off What the Fed Is Saying About RatesForeign Investors Have Been Propping Up US Bond Market This YearMacron’s Election Gamble Gives Europe Brexit Nightmares AgainRoaring Kitty’s $262 Million Stirs Skeptics in Meme Stock EraA 140-Year-Old New York College Has Ratings Slashed to...

Here's how to reduce your premiumsBenefits await gig workers who come clean with CRASick of extra fees online? It's drip pricing, and Canadian shoppers are fighting backFrance Prepares for Far-Right Protests as Le Pen Leads the PollsExpress Sale to WHP Global-Led Group for $174 Million ApprovedNiger Stops Chinese Oil Exports Through Benin Over Border FeudKraken Owner Holloway Builds on Seattle Vision With NBA HopesKuehne Owner Sees Triple-Digit Million Hit on Signa InvestmentBlackstone...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in HEALTH

Health Health Latest News, Health Health Headlines